John Lunec

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Clinical Evaluation

Cell Cycle Arrest

Chronic Lymphocytic Leukemia

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Combination p53 activation and BCL-x L /BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38 (6) (2024)
Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, Elaine Willmore, John Lunec
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines 12 (7) (2024)
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Combination p53 activation and BCL-x L /BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38 (6) (2024)
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Combination p53 activation and BCL-x L /BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia (2024)
Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, Elaine Willmore, John Lunec
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines 12 (7) (2024)
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Combination p53 activation and BCL-x L /BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38 (6) (2024)
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Combination p53 activation and BCL-x L /BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 38 (6) (2024)
Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, Elaine Willmore, John Lunec
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines 12 (7) (2024)
Erhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International journal of molecular sciences 24 (3) (2023)
Erhan Aptullahoglu, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International journal of molecular sciences 24 (14) (2023)
Erhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International journal of molecular sciences 24 (3) (2023)
Erhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International journal of molecular sciences 24 (3) (2023)
Erhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International journal of molecular sciences 24 (3) (2023)
Victoria Chamberlain, Yvette Drew, John Lunec
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53 WT Uterine Leiomyosarcoma. Cancers 14 (1) (2021)
Chiao-En Wu, Tsin Shue Koay, Arman Esfandiari, Yi-Hsuan Ho, Penny Lovat, John Lunec
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. Cancers 11 (1) (2018)